Zura Bio Limited Class A Ordinary Shares (ZURA) Stock Forecast & Price Target
Zura Bio Limited Class A Ordinary Shares · NASDAQ
$5.37+0.14 (+2.68%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Zura Bio Limited Class A Ordinary Shares, 5 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $2.00 to $18.00 (about 9.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $12.20 sits 127% above the current $5.37. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 4 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.18 next quarter toward $-0.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy583%
Hold117%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Zura Bio Limited Class A Ordinary Shares.
As of Jul, 5 of 6 firms rate ZURA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ZURA EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.19 – $-0.17 · 3 analysts
Next period, 3 analysts expect Zura Bio Limited Class A Ordinary Shares to earn $-0.18 a share (range $-0.19 – $-0.17), versus — a year earlier. Full-year consensus is $-0.72, growing to $-0.55 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $10.7M next year.
Top analysts covering Zura Bio Limited Class A Ordinary Shares
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZURA.
#1
Yatin Suneja
Guggenheim · Rank #28
Buy
$15.00+179.3% to target
Overall win rate
52%
+ Follow
#2
Daniil Gataulin
Chardan Capital · Rank #36
Buy
$11.00+104.8% to target
Overall win rate
55%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #140
Buy
No targeton ZURA
Overall win rate
38%
+ Follow
#4
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$26.00+384.2% to target
Overall win rate
34%
+ Follow
#5
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Hold
$2.00-62.8% to target
Overall win rate
34%
+ Follow
ZURA stock forecast FAQ
What is ZURA's average 12-month price target?+
The 5 analysts with a live target average $12.20 for Zura Bio Limited Class A Ordinary Shares over the next 12 months, ranging from a $18.00 high to a $2.00 low.
Is ZURA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 5 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ZURA?+
The Street-high target is $18.00 (Clear Street), and the Street-low is $2.00 (HC Wainwright & Co.). The average of all 5 active targets is $12.20.
How many Wall Street analysts cover ZURA?+
6 analysts have an active rating on Zura Bio Limited Class A Ordinary Shares, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering ZURA?+
Among analysts who currently cover ZURA, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #28). Their current call is Buy with a $15.00 target.
What is Zura Bio Limited Class A Ordinary Shares's projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.19 – $-0.17) across 3 analysts. Full-year EPS is projected at $-0.72, rising to $-0.55 the following year.
How much revenue is Zura Bio Limited Class A Ordinary Shares expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $10.7M next year.
Have analysts been upgrading or downgrading ZURA lately?+
As of Jul, 5 of 6 firms rate ZURA a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZURA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
